IMUX

Immunic Inc

7.52

Nov 13 • 3:59 PM ET -0.27 (-3.47%)

7.60

Aftermarket • 7:36 PM ET +0.08 (1.06%)

Healthcare Biotechnology USA Micro NASD

Nov 13, 10:16 AMImmunic says twin Phase 3 ENSURE trials in relapsing MS are fully enrolled, with top-line data expected in December

Peers: CTNM TGTX CLNN BIIB RNAC ABVX IMVT ATRA SNY NVS

| Held by: VTI VXF IWC SURI AVSC SBIO QQQS

Scroll to Statements

Index	-
Market Cap	102.61M
Enterprise Value	-29.10M
Income	-128.30M
Sales	0.00M
Book/sh	6.58
Cash/sh	9.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	92
IPO	Apr 17, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.14
P/C	0.78
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.28
Current Ratio	4.28
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.48
EPS next Y	-2.41
EPS next Q	-0.80
EPS this Y	40.55%
EPS next Y	34.60%
EPS next 5Y	26.21%
EPS past 3/5Y	45.16% 25.99%
Sales past 3/5Y	- -
EPS Y/Y TTM	48.29%
Sales Y/Y TTM	-
EPS Q/Q	25.06%
Sales Q/Q	-
Earnings	Nov 13 BMO
EPS/Sales Surpr.	-26.08% -

Insider Own	6.52%
Insider Trans	0.00%
Inst Own	81.66%
Inst Trans	12.49%
ROA	-144.86%
ROE	-223.18%
ROIC	-122.80%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.09%
SMA50	-13.55%
SMA200	-34.96%
Trades

Shs Outstand	15.88M
Shs Float	12.76M
Short Float	15.28%
Short Ratio	5.79
Short Interest	1.95M
52W High	17.43 -56.86%
52W Low	5.06 48.56%
Volatility	6.21% 7.68%
ATR (14)	0.59
RSI (14)	43.46
Beta	1.48
Rel Volume	0.31
Avg Volume	336.67K
Volume	105,549

Perf Week	-2.97%
Perf Month	5.92%
Perf Quarter	-53.09%
Perf Half Y	-37.75%
Perf YTD	40.90%
Perf Year	5.54%
Perf 3Y	-22.42%
Perf 5Y	-92.25%
Perf 10Y	-99.69%
Recom	1.00
Target Price	42.64
Prev Close	7.79
Price	7.52
Change %	-3.47%

Consensus

Strong Buy

Avg. Price Target

$42.64

Implied Upside

+467.0%

Analysts17incl. previous ratings

Rating Distribution15 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 23, 2026	Initiated	CCantor Fitzgerald	Overweight
Aug 17, 2026	Initiated	WWedbush	Outperform	$45	+498.4%
May 22, 2026	Initiated	WWolfe Research	Outperform
Apr 17, 2026	Initiated	SStifel	Buy	$2.50	-66.8%
Apr 15, 2026	Downgrade	DD. Boral Capital	Buy → Hold
Mar 24, 2026	Initiated	GGuggenheim	Buy	$7	-6.9%
Nov 07, 2025	Initiated	RRoth Capital	Buy	$3	-60.1%
Sep 29, 2025	Initiated	CChardan Capital Markets	Buy	$13	+72.9%
Mar 25, 2025	Initiated	WWilliam Blair	Outperform
Nov 25, 2024	Initiated	HH.C. Wainwright	Buy	$10	+33.0%
Sep 09, 2024	Resumed	LLeerink Partners	Outperform	$5	-33.5%
Aug 27, 2024	Initiated	RB. Riley Securities	Buy	$6	-20.2%
Oct 21, 2022	Downgrade	SSVB Leerink	Outperform → Mkt Perform	$5	-33.5%
Sep 19, 2022	Resumed	HH.C. Wainwright	Buy	$26	+245.7%
Apr 15, 2021	Initiated	AAegis Capital	Buy	$55	+631.4%
Mar 24, 2021	Initiated	JJMP Securities	Mkt Outperform	$55	+631.4%
Oct 02, 2020	Initiated	SSVB Leerink	Outperform	$45	+498.4%
Aug 26, 2020	Initiated	PPiper Sandler	Overweight	$71	+844.1%
Aug 07, 2020	Resumed	RROTH Capital	Buy	$64	+751.1%
Jul 20, 2020	Initiated	BBMO Capital Markets	Outperform	$40	+431.9%

Nov-13-26 09:10AM	Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027 (Proactive)
08:47AM	Why Is Immunic Stock Falling 5% Following Its Third-Quarter Results? (InvestorsHub)
07:14AM	Immunic shares fall 5% on third quarter earnings miss (Investing.com)
06:56AM	MARKETS LIVE: Wall Street ends volatile week mixed as Nvidia selloff weighs on tech stocks (Proactive)
06:36AM	Immunic: Q3 Earnings Snapshot (Associated Press)
06:30AM	Loading…
06:30AM	Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-02-26 06:30AM	Immunic to Participate in Investor Conferences in November (PR Newswire)
Oct-29-26 10:29AM	Immunic to host R&D Day on progressive multiple sclerosis (Proactive)
06:30AM	Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 (PR Newswire)
Oct-21-26 07:00AM	Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting (PR Newswire)
Oct-19-26 08:27AM	Immunic adds new Chief People Officer ahead of Phase 3 readout (Proactive)
06:30AM	Immunic Appoints Jaa Roberson as Chief People Officer (PR Newswire)
Oct-07-26 11:04AM	Immunic to present four vidofludimus calcium abstracts at MSToronto2026 (Proactive)
08:00AM	Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting (PR Newswire)
Sep-02-26 08:40AM	Immunic to host virtual relapsing MS R&D Day on September 9 (Proactive)
06:30AM	Loading…
06:30AM	Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 (PR Newswire)
Sep-01-26 08:36AM	Immunic appoints Chitrang Davé as chief data and digital officer (Proactive) -7.72%
07:41AM	Nasdaq tumbles as rising yields fuel market selloff (Proactive)
06:30AM	Immunic Appoints Chitrang Dave as Chief Data and Digital Officer (PR Newswire)
Aug-11-26 08:36AM	Immunic advances MS drug toward key Phase 3 data, expects results by year-end (Proactive) +9.79%
06:34AM	Immunic: Q2 Earnings Snapshot (Associated Press)
06:30AM	Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Aug-10-26 04:05PM	Immunic Appoints Elena Ridloff to Board of Directors (PR Newswire)
03:07PM	Immunic CEO on Q2 progress and Phase 3 MS trial milestones (Proactive)
Jul-09-26 06:30AM	Immunic to Participate in Investor Conferences in July (PR Newswire)
Jun-10-26 06:30AM	Immunic to Participate in Investor, Industry and Scientific Conferences in June (PR Newswire)
May-28-26 10:29AM	Immunic presents new vidofludimus calcium data at multiple sclerosis conference (Proactive) +6.93%
06:30AM	Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis (PR Newswire)
May-27-26 09:06AM	Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials (Proactive) +7.94%
06:30AM	Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer (PR Newswire)
09:33AM	Loading…
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
06:30AM	Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors (PR Newswire)
May-13-26 09:04AM	Immunic advances Phase 3 MS program, eyes topline data by year-end (Proactive) +8.82%
07:48AM	Nasdaq continues to gain but Dow still red as Trump arrives in China (Proactive)
06:35AM	Immunic: Q1 Earnings Snapshot (Associated Press)
06:30AM	Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
May-07-26 08:47AM	Immunic CEO on Q1 highlights, new appointments and upcoming milestones (Proactive) +6.62%
Apr-30-26 06:30AM	Immunic to Participate in Investor and Medical Conferences in May (PR Newswire)
Apr-28-26 08:40AM	Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout (Proactive) +7.72%
06:30AM	Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer (PR Newswire)
Apr-23-26 08:52AM	Immunic to implement 1-for-10 reverse stock split (Proactive)
08:00AM	Immunic, Inc. Announces 1-for-10 Reverse Stock Split (PR Newswire)
Apr-09-26 06:30AM	Immunic to Participate in Scientific and Medical Conferences in April (PR Newswire) +8.40%
Apr-07-26 08:05AM	Immunic COO highlights the importance of science-led innovation to mark World Health Day (Proactive)
Apr-01-26 06:30AM	Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +7.77%
06:30AM	Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton (PR Newswire)
Mar-10-26 08:36AM	Immunic secures European patent for MS drug candidate vidofludimus calcium (Proactive)
06:30AM	Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium (PR Newswire)
Mar-03-26 07:08AM	Immunic to present at healthcare investor conferences in March (Proactive)
06:30AM	Immunic to Participate in Investor Conferences in March (PR Newswire)
Feb-28-26 03:00PM	Immunic secures $400M to support late-stage MS trials - ICYMI (Proactive)
Feb-26-26 09:02AM	Immunic sets stage for phase 3 MS data readout after $400M financing (Proactive)
07:08AM	Immunic: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update (PR Newswire)
Feb-17-26 04:33PM	Immunic closes $200M private placement to fund late-stage MS trials (Proactive)
04:05PM	Immunic Announces Closing of Oversubscribed Private Placement Financing (PR Newswire)
Feb-16-26 06:09AM	Immunic secures $400m fund to support commercial-stage development (Pharmaceutical Business Review)
Feb-14-26 08:15AM	Immunic MS trial shows reduced brain lesions - ICYMI (Proactive)
Feb-13-26 01:55PM	Why Is Immunic Stock Soaring Friday? (Benzinga)
11:25AM	Immunic Stock Jumps After Pricing $400 Million Private Placement (Benzinga)
11:20AM	Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push (Proactive)
09:03AM	Immunic to raise up to $400M to fund late-stage MS trials, commercial push (Proactive)
06:30AM	Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company (PR Newswire)
Feb-10-26 08:11AM	Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum (Proactive) +11.30%
Feb-04-26 08:45AM	Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS (Proactive) -5.43%
06:30AM	Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis (PR Newswire)
Jan-12-26 04:23AM	Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% (Insider Monkey)
Jan-07-26 06:30AM	Immunic Highlights 2025 Accomplishments and Upcoming Milestones (PR Newswire) +10.67%
Nov-26-25 06:30AM	Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December (PR Newswire)
Nov-13-25 06:39AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance) -6.24%
06:30AM	Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 06:30AM	Immunic to Participate in Industry and Investor Conferences in November (PR Newswire) -5.01%
Oct-01-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in October (PR Newswire) +8.89%
Sep-25-25 06:30AM	Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
Sep-09-25 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis (PR Newswire)
Sep-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in September (PR Newswire)
Aug-07-25 06:37AM	Immunic: Q2 Earnings Snapshot (Associated Press Finance) -7.87%
06:30AM	Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Jul-25-25 12:22PM	Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial (Insider Monkey)
Jun-24-25 06:30AM	Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis (PR Newswire)
Jun-05-25 06:30AM	Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS (PR Newswire)
Jun-03-25 04:01PM	Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering (PR Newswire) +6.11%
Jun-02-25 06:30AM	Immunic to Participate in Investor, Scientific and Industry Conferences in June (PR Newswire) +6.08%
May-29-25 07:05AM	Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering (PR Newswire) -25.28%
May-28-25 04:02PM	Immunic, Inc. Announces Proposed Public Offering (PR Newswire)
May-15-25 06:24PM	Immunic: Q1 Earnings Snapshot (Associated Press Finance)
May-02-25 06:30AM	Immunic to Participate in Scientific and Industry Conferences in May (PR Newswire)
May-01-25 01:56PM	Immunic presses ahead with MS drug despite Phase II endpoint miss (Clinical Trials Arena) +18.17%
Apr-30-25 07:30AM	Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial (PR Newswire) -22.65%
Apr-28-25 02:09AM	Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (Seeking Alpha)
Apr-10-25 01:00PM	Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-09-25 08:10AM	Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-01-25 06:30AM	Immunic, Inc. to Participate in Scientific and Industry Conferences in April (PR Newswire)
Mar-03-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in March (PR Newswire)
Feb-26-25 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
Feb-20-25 07:30AM	Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing (PR Newswire) +12.38%
Feb-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-07-25 06:30AM	Immunic Highlights 2024 Accomplishments and Upcoming Milestones (PR Newswire)

Show Previous News

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

COO & PresidentMr. Jason Tardio M.B.A.

Chief Financial OfficerMr. Glenn Whaley CPA

CEO & DirectorMr. Erik Lundgren

Co-Founder & Chief Scientific OfficerDr. Hella Kohlhof

Vice President of Investor Relations & CommunicationsMs. Jessica Breu

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

IMUX

Immunic Inc

Upgrade your Finviz experience

All the Features.
Half the Price.